Vivani Medical VANI Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Income Loss by Business | ||||||
| Biopharm Division | -$24.52M-1.5% | -$24.15M-2.8% | -$23.48M-2.0% | -$23.02M-7.3% | -$21.45M-0.9% | |
| Other Nonoperating Income Expense by Business | ||||||
| Biopharm Division | $910K+10.6% | $823K-39.1% | $1.35M+5.4% | $1.28M-0.2% | $1.29M-4.6% | |
| Operating Expenses by Business | ||||||
| Biopharm Division | $25M0.0% | $25M— | —— | —— | —— | |
| Total Assets by Business | ||||||
| Biopharm Division | $133.6M+5.7% | $126.4M— | —— | —— | —— | |
| Other General And Administrative Expense by Business | ||||||
| Biopharm Division | $909K+15.9% | $784K-1.4% | $795K-8.2% | $866K+1.9% | $850K+4.6% | |
| Operating Lease Expense by Business | ||||||
| Biopharm Division | $4.28M+1.5% | $4.21M-0.3% | $4.23M-1.1% | $4.27M+3.6% | $4.12M+3.1% | |
| Labor And Related Expense by Business | ||||||
| Biopharm Division | $10.41M+1.3% | $10.28M+2.1% | $10.07M-0.7% | $10.13M+1.0% | $10.04M-0.2% | |
| Depreciation And Amortization by Business | ||||||
| Biopharm Division | $441K+7.6% | $410K+5.1% | $390K+0.5% | $388K+0.8% | $385K+1.9% | |
| Professional Services And Insurance Expense by Business | ||||||
| Biopharm Division | $4.65M-5.3% | $4.91M-5.0% | $5.17M+4.3% | $4.96M+9.8% | $4.51M-1.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Vivani Medical break its business down?
- Vivani Medical (VANI) reports net income loss by business across 3 parts — Biopharm Division, Neuromodulation Division and Neurostimulation Division. Each is extracted from the segment footnotes and tracked over time.
- Where does Vivani Medical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vivani Medical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.